EP Patent

EP2573082A1 — Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2013-03-27 · 13y expired

What this patent protects

The novel methanol solvate, ethanol solvate, ethanol·hydrate and isopropanol·hydrate crystals of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; pharmaceutical agents which comprise these crystals; and their use for the prophylaxis or tr…

USPTO Abstract

The novel methanol solvate, ethanol solvate, ethanol·hydrate and isopropanol·hydrate crystals of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; pharmaceutical agents which comprise these crystals; and their use for the prophylaxis or treatment of digestive ulcer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2573082A1
Jurisdiction
EP
Classification
—
Expires
2013-03-27
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.